Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Combined With Bevacizumab in EGFR-Mutated NSCLC With Brain Metastasis
NCT05104281Phase 3Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of osimertinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Progression-Free Survival at 30 months. Status: unknown.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05104281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104281.